Neoadjuvant chemoradiotherapy demonstrates a long-term survival benefit in pancreatic cancer patients when compared to upfront surgery
1. The use of a neoadjuvant gemcitabine-based chemoradiotherapy before surgery and adjuvant gemcitabine increased the overall survival rate when compared ...